Huile Gao

Biography

Dr. Huile Gao received his PhD in Pharmaceutics from School of Pharmacy, Fudan University in 2013 under the supervision of Prof. Xinguo Jiang. Then he joined the West China School of Pharmacy, Sichuan University as an Instructor in July 2013 and was promoted to an Associate Professor in July 2014. He was a visiting scholar of Stanford University from Oct. 2015 to Oct. 2016. Dr. Gao’s research interests focus on the design, synthesis, characterization and evaluation of stimuli responsive nanomaterials for drug and imaging probe delivery to improve treatment and diagnosis of human diseases especially tumor and brain diseases. He has published over 100 peer-reviewed articles with an H-index of 28. His research is supported by National Natural Science Foundation of China (81373337, 81402866), Excellent young scientist foundation of Sichuan University (2015SCU04A14) and other grants. His doctorial dissertation has been awarded as Excellent Doctorial Dissertation of Shanghai in 2015, and He was awarded as Young Pharmaceutics Scientist by Chinese Pharmaceutical Association in 2015. He served as editor of the book “neurotoxicity of nanomaterials and nanomedicines”, and guest editor for the Current Drug Metabolism. He is now serving as Editorial Board Member of Current Drug Metabolism, Journal of Microencapsulation, EC Pharmacology and Toxicology, Acta Pharmaceutica Sinica, and Chinese Journal of Hospital Pharmacy.

Research Interest

RESEARCH INTEREST Dr. Gao’s current research involves nanotechnology and nanomaterials for cancer diagnosis and therapeutics. From understanding nanotechnology to biomedical application and pharmaceutical development, the work is closely related to seeking the potentials for highly tumor specific targeting delivery using both biomaterials and inorganic materials originated nanovesicles. (1) Size shrinkable nanoparticles. Dendritic poly-L-lysine (DGL) and gold nanoparticles were fabricated with gelatin nanoparticles to construct nanoparticles with large size, which could retain in tumor site by ligand-mediated active targeting and EPR effect. Then the particles were degraded by MMP-2 in tumor and the DGL and gold nanoparticles with small size were released to further penetrate into deep tumor, resulting in better anti-tumor effect. (2) Tumor in situ gel. Injectable in situ gel is rare studied. In my lab, a pH response material was developed. When the material reached tumor through blood circulation, the reaction group was exposed due to the low pH value in tumor, and then the material was polymerized by Click reaction. (3) The influence of protein corona on ligand mediated targeting delivery. Using gold nanoparticles, RGD peptide and transferrin protein as model, I try to evaluate the effect of protein corona on small peptide and large protein mediated active targeting. However, due to the lack of key equipment, this study is still premature for me.